

Special Article - T-Cell Lymphoma

Treatment Options of Mature, Nodal T-Cell Lymphomas

Illés Á and Miltényi Z*

Department of Hematology, University of Debrecen, Hungary

*Corresponding author: Zsófia Miltényi, Department of Hematology, University of Debrecen, Nagyerdei krt. 98 4032 Debrecen, Hungary

Received: July 06, 2016; Accepted: August 02, 2016;

Published: August 04, 2016

Abstract

T-cell lymphomas represent only 10-15% of non-Hodgkin lymphomas. T cell lymphomas are more aggressive, heterogeneous diseases and have worse prognosis than B cell lymphomas. A number of new drugs are tested and approved in the therapy of peripheral T cell lymphomas, which hopefully will increase survival. CHOP and CHOP-like protocol are recommended for the first-line treatment, but its efficacy alone only in ALK+ anaplastic large cell lymphoma. Guidelines recommend front-line autologous hematopoietic stem cell transplantation in the other most frequent subtypes. A number of new drugs are tested and approved in the therapy of peripheral T cell lymphomas, eg. romidepsin, pralatrexate, belinostat, brentuximab vedotin etc., which hopefully will increase survival.

Keywords: T cell lymphoma; Treatment; New drugs

Abbreviations

AE: Adverse Event; AHSCT: Autologous Hemopoetic Stem Cell Transplantation; AITL: Angioimmunoblastic T Cell Lymphoma; ALCL: Anaplastic Large Cell Lymphoma; ALK: Anaplastic Lymphoma Kinase; CHOP: Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CHOEP: CHOP+etoposide; CR: Complete Remission; EFS: Event-Free Survival; FDA: Food and Drug Administration; FFS: Failure-Free Survival; HDAC: Histone Deacetylase; NCCN: National Comprehensive Cancer Network; NHL: Non-Hodgkin Lymphoma; OS: Overall Survival; PFS: Progression-Free Survival; PTCL-NOS: Peripheral T-Cell Lymphoma Not Otherwise Specified; TCL: T Cell Lymphoma; WHO: World Health Organization

Introduction

Non-Hodgkin lymphomas (NHLs) originate from T lymphocytes and NK cells in 10-15% of cases, while T-cell lymphomas (TCL) represent approximately 25% of NHLs in Asian countries [1]. There are four main groups of T cell lymphomas in the WHO classification: nodal, extranodal, cutan and leukemic group. New provisional entities of T cell lymphomas are introduced in the new WHO 2016 classification, these changes mostly based on the result of genomic studies [2]. Three subtypes are the most frequent in nodal T cell lymphoma group: peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and systemic anaplastic large cell lymphoma (ALCL), which may be positive or negative for anaplastic lymphoma kinase (ALK) [2]. T cell lymphomas are more aggressive, heterogeneous diseases and have worse prognosis than B cell lymphomas. Usually patients have advanced stage disease and extranodal involvement at the time of diagnosis. The minority of patients reach durable remissions or cure after first-line treatment. Treatment of TCLs is unmet medical need nowadays. A number of new drugs are tested and approved in the therapy of PTCLs, which hopefully will increase survival.

Current first-line treatment options

Majority of PTCLs, except for ALK+ ALCL, has bad prognosis. The 5-year overall survival (OS) for ALK+ ALCL, ALK-ALCL,

PTCL-NOS and AITL was 70%, 49%, 32% and 32% and the 5-year failure-free survival (FFS) was 60%, 36%, 20% and 18% [3]. The frontline treatment in the most frequent PTCL types is combination chemotherapy, usually anthracycline-based regimens, such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone), or CHOP+etoposide (CHOEP) with autologous hematopoietic stem cell transplantation (AHSCT) given as consolidation for high risk, selected patients (except ALK+ ALCL) [4,5].

CHOP is the generally recommended and used protocol, but it has moderate efficacy. A retrospective analysis showed 5-year OS was only 37% in 2912 patients, who received CHOP or CHOP-like chemotherapy [6]. The only exception was ALK+ and ALK - ALCL, which has better survival, overall response rate (ORR) >75% and 5-year OS >60% [7]. PTCL-NOS patients who received anthracycline in the initial treatment has no survival benefit than patients who didn't receive it [3].

There were a lot of trials to improve efficacy of the therapy. Some studies used combination therapy eg. CHOP plus etoposid or alemtuzumab, or another chemotherapy eg. ACVBP, VIP-rABDV, alemtuzumab, denileukin diftitox [8]. VIP/ABVD (etoposide/ ifosfamide/ cisplatin-doxorubicin/ bleomycin/ vinblastine/ dacarbazine), CHOP/ESHAP did not improve the outcome [9-11]. Hyper-CVAD/MA (hyper-fractionated cyclophosphamide/ doxorubicin/ vincristine/ dexamethasone alternating with methotrexate/ cytarabine) showed higher ORR and progression-free survival (PFS), but not higher OS, than CHOP [12] in a retrospective study, but this regimen associated with greater toxicity.

The German High-Grade Lymphoma Study Group added etoposide to CHOP (CHOEP) [13]. ORR was 82% and complete remission) CR was 63%. Schmitz, et al. reported that CHOEP treatment is more effective than CHOP in young patients' group, but this treatment was no significantly better in >60 years old patients and it was too toxic in this group [13].

The difference in event-free survival (EFS) for younger patients and ALK+ ALCL treated with CHOP or CHOEP was significant (3-year EFS for CHOEP patients 91.2% vs. 57.1% for patients treated

Table 1: New first line treatment options.

First line treatment	ORR	CR	grade 3/4 toxicities	comment
CHOEP [13]	82%	63%		
CHOP+romidepsin [22]	69%	51%	neutropenia 89%	
romidepsin-CHOP [54]	78%	66%		
Brentuximab vedotin-CHP [47]	100%	88%	febrile neutropenia 31%	only CD30+PTCL
bortezomib-CHOP [50]	76%	65%	neutropenia 41%	
everolimus-CHOP [55]	90%	57%	neutropenia 80%	all AITL were in CR
alemtuzumab-CHOP [57]	68%	37%	neutropenia 70%	only CD52+PTCL
pralatrexate-CEOP [58]	70%	52%	anaemia 27 %	

(ORR: overall response rate, CR: complete response)

Table 2: New salvage treatment options.

Salvage treatment	ORR	CR	grade 3/4 toxicities	comment
pralatrexate [20]	29%	11%	thrombocytopenia 33%	AITL had fewer response
romidepsin [21]	38%	18%		
belinostat [23,24]	26%	11%	thrombocytopenia 13%	AITL had ORR 46%
brentuximab vedotin [25]	86%	57%	neutropenia 21%	
bendamustin [28]	50%	28%	neutropenia 30%	
mogamulizumab [29]	50%	31%	lymphopenia 74%	only CCR4+ TCL
mogamulizumab [30]	35%	14%	lymphopenia 73%	only CCR4+ TCL
zanolimumab [31]	24%	10%	lymphopenia 10%	only CD4+ TCL
lenalidomide [32]	30%	0%	thrombocytopenia 42%	
lenalidomide [33]	22%	11%	thrombocytopenia 20%	
alisertib [35]	50%		neutropenia 63%	
crizotinib [37,38]	91%	27%		only ALK+ ALCL
gemcitabin [39]	55%	30%		
bortezomib [40]	67%	13%	neutropenia 13% (only grade3)	
everolimus [44]	44%	6%	anaemia 25%	
duvelisib [45]	47%	13%		
nivolumab [46]	17%			ORR: 40 % in PTCL patients
bortezomib-gemcitabin [51]	36%	27%		
gemcitabin-romidepsin [52]	30%	15%	thrompocytopenia 60%	
gemcitabin-dexamethason-cisplatin [53]	72%	48%	neutropenia 16%	

(ORR: overall response rate, CR: complete response)

with CHOP, $p = 0.012$), a statistically not significant difference was seen in the remaining patients when ALK+ ALCL was excluded (3-year EFS for CHOEP patients 60.7% vs. 48.3% for patients treated with CHOP, $p = 0.057$) [13].

CHOEP was associated with improved PFS in patients younger than 60 years in a Swedish analysis also [14].

Autologous transplantation is recommended ALK-ALCL patients in first-line treatment, but not in ALK+ALCL patients [5]. D'Amore, et al. showed 5-year OS 70% and PFS 61% in ALK-ALCL patients who were treated 6 cycles CHOEP followed by AHSCT, if they were in CR/CRu or PR [15]. AHSCT produces better 5-year OS in ALK+ than ALK-patients (82% versus 54%) [16].

Based on these results National Comprehensive Cancer Network (NCCN) guidelines recommend CHOP-21 or CHOEP-21 regimens

as the first-line therapy in ALK-positive ALCL and clinical trials and/or frontline AHSCT for first-line therapy in all other subtypes [5].

New therapeutic options

Only half of the TCL patients reached complete remission (CR) after first line treatment and only half of these patients have durable remission [17]. Majority of T-cell lymphoma patients (about 70%) have refractory disease or relapse after the first line treatment [4]. Relapsed/refractory (R/R) PTCL patients' overall survival (OS), who did not undergo AHSCT, 5.5 months only [18].

There is no uniform recommendation to the optimal treatment relapsed and refractory patients. A lot of clinical trials was conducted and these showed various efficacy (Table 1,2). Three new drugs was approved by the FDA in the therapy of R/R PTCL patients, pralatrexate, romidepsin and belinostat.

FDA approved new drugs

Pralatrexate: Pralatrexate, an antimetabolite drug, which selectively enters cells through reduced folate carrier type 1, FDA approved this drug for the treatment of patients with R/R PTCL in 2009. O'Connor, et al. conducted a dose/schedule finding study in R/R lymphomas [19]. ORRs were 10% and 54% in patients with B-cell and T-cell lymphomas respectively. All eight patients who achieved CR had T-cell lymphoma. PROPEL was the first international prospective study of novel therapeutic agents in patients with PTCL [20]. One hundred and nine heavily pretreated PTCL patients received the drug, ORR and CR/CRu (CR unconfirmed) rates were 29% and 11%. Patients with AITL had fewer responses (1 out of 13 patients) than other subtypes. Patients who received only CHOP before pralatrexate, the ORR was 47% and the CR rate was 30%, suggesting that the response rate might be higher if pralatrexate is used earlier, not in heavily pretreated patients. Grade 3/4 adverse events (AEs) were thrombocytopenia (33%), mucositis (22%), neutropenia (22%) and anemia (18%) [20].

Romidepsin: Romidepsin is a new potent class I selective histone deacetylase (HDAC) inhibitor, which was approved by the FDA in 2011 for the treatment of PTCL in patients who had received ≥ 1 prior therapies. A phase II trial used romidepsin in 47 PTCL patients with various histologic subtypes [21]. Among 45 evaluable patients in this study ORR was 38% and 18% had CR. The most common AEs were nausea (51%), thrombocytopenia (47%), leukopenia (47%), granulocytopenia (45%), fatigue (40%) and anemia (40%) [21]. One hundred and thirty patients were treated with romidepsin in another phase II trial. Most patients had PTCL-NOS ($n=69$), AITL ($n=27$), or ALK-negative ALCL ($n=21$). The ORR was 25% and 15% had CR. The most common grade 3/4 AEs were thrombocytopenia (24%), neutropenia (20%) and infections (19%).

Single-arm, phase Ib/II study used CHOP plus romidepsin as first line treatment in 37 PTCL patients. Among 35 evaluable patients the ORR was 69% and CR was 51%. Three patients had early cardiac events, including two myocardial infarctions and one acute cardiac failure. The most frequent serious AEs were febrile neutropenia 14%, physical health deterioration and lung infection 11%. Grade 3/4 neutropenia were detected in 89% of patients and grade 3/4 thrombocytopenia in 78% [22].

Belinostat: Belinostat is a pan-HDAC inhibitor, which was investigated in R/R PTCL patients in the BELIEF trial. One hundred and twenty-nine patients received belinostat, among the 120 evaluable patients, the ORR was 26%, CR was 11%. ORR was the best, 46% in AITL. The most common grade 3/4 AEs were thrombocytopenia (13%), neutropenia (13%) and anemia (10%) [23,24]. Based on the results of this study FDA approval belinostat in 2014 for treatment of R/R PTCL patients.

Other new therapeutic options

Monotherapy: Brentuximab vedotin: Brentuximab vedotin (BV) is an immunconjugate of an antitubulin agent and a CD30-specific immunoglobulin G1 monoclonal antibody. Fifty eight ALCL patients were treated with BV in a phase II study, ORR was 86% and CR was 57%. The most common AEs were peripheral sensory neuropathy (41%), nausea (40%), fatigue (38%) and pyrexia (34%). Based on the

results of this study, the FDA and European Medicines Agency, in 2011 and 2012, approved the use of BV for patients with systemic ALCL after failure of ≥ 1 multi-agent chemotherapy regimen [25]. Another phase II trial of BV in 35 patients showed ORR of 41% and no correlation between CD30 expression per central review and response was observed [26]. Grade 3/4 adverse events were neutropenia (21%), thrombocytopenia (14%) and peripheral sensory neuropathy (12%) [27].

Bendamustine: Bendamustine is an alkylating agent with antimetabolite effect. In the BENTLY trial, 60 patients with CTCL and PTCL (mainly AITL and PTCL-NOS) were treated with bendamustine. The ORR was 50% and CR was 28%. The most frequent grade 3/4 AEs were neutropenia (30%), thrombocytopenia (24%) and infections (20%) [28].

Mogamulizumab: Mogamulizumab is an anti-CC chemokine receptor 4 (CCR4) monoclonal antibody. Mogamulizumab depletes CCR4-positive regulatory T cells and help to enhance antitumor activity. Twenty-seven relapsed aggressive CCR4-positive T cell lymphoma patients received mogamulizumab in a phase II study. ORR was 50% and CR was 31%. The most common grade 3/4 AEs were lymphopenia (74%), leukocytopenia (30%), thrombocytopenia (19%), neutropenia (19%) and rash (19%) [29]. Another phase II study of mogamulizumab at the same dose in 38 patients, of whom 37 were evaluable with relapsed CCR4-positive PTCL or CTCL, reported an ORR of 35%, including 14% with a CR. The most common grade 3/4 AEs were lymphopenia (73%) and neutropenia (19%) also [30].

Zanolimumab: Zanolimumab is an anti-CD4 monoclonal antibody. Twenty-one R/R CD4+ PTCL patients were treated with zanolimumab ORR was 24% and CR was 10%. Grade 3 AEs were lymphopenia (10%), infusion-related AEs (10%) and arthralgia (5%) [31].

Lenalidomide: Lenalidomide is an immunomodulatory drug which inhibits vascular endothelial growth factor (VEGF), activation of natural killer cells and T lymphocytes and modulates various cytokines such as tumor necrosis factor- α , interleukin-12 and interferon- γ . A phase II study used lenalidomide in 24 patients. Among the 23 evaluable patients, ORR was 30%, but there are no patients in CR. The most common grade 3/4 AEs were thrombocytopenia (42%), neutropenia (21%), dyspnea (17%), febrile neutropenia (17%), pain (17%) and pneumonitis (17%) [32]. EXPECT was an phase II study which included 54 patients with R/R PTCL. ORR was 22%, CR/CRu was 11%. Most common grade 3/4 AEs were thrombocytopenia (20%), gastrointestinal disorders (17%), neutropenia (15%) and infections (15%) [33].

Alisertib: Aurora A kinase (AAK) is a mitotic kinase which is upregulated in PTCL [34]. Alisertib is an oral selective AAK inhibitor, a phase II trial evaluated its efficacy in refractory T-cell and B-cell lymphomas. ORR was 50% in eight PTCL patients. Grade 3/4 AEs were neutropenia 63%, leukopenia 54%, anemia 35%, thrombocytopenia 33% and stomatitis 15% [35]. Thirty-seven R/R PTCL patients were treated in another phase II intergroup trial (SWOG 1108). Among ORR was 30% Grade 3/4 AEs were neutropenia (32%), anemia (30%), thrombocytopenia (24%), febrile neutropenia (14%), mucositis (11%) and rash (5%). Based on these results, a randomized phase III trial of

alisertib versus the investigator's choice (pralatrexate or gemcitabine monotherapy) was designed for patients with relapsed PTCL, but study was closed earlier due to alisertib was not more effective than other treatments [17,36].

Crizotinib: Crizotinib is an oral small-molecule tyrosine kinase inhibitor of ALK, which has been FDA approved for the treatment of lung cancer. Eleven refractory ALK+ lymphoma patients (9 ALCL) received crizotinib ORR was 91%, CR was 27%. There were no grade 3/4 toxicity [37,38]. A clinical trial is ongoing in ALK+ ALCL patients with use of crizotinib.

Gemcitabine: Gemcitabine is a nucleoside analog, which inhibits DNA replication and repair. Other nucleoside analogs are pentostatin, cladribine, fludarabine, clofarabine, forodesine and nelarabine. These agents are cytotoxic to both proliferating and non-proliferating cells. Gemcitabine, cladribine and fludarabine have shown efficacy in PTCL and gemcitabine is the most effective in PTCL. NCCN guidelines recommends as second-line therapy for patients with relapsed PTCL [5]. Twenty R/R PTCL-NOS patients were treated with gemcitabine [39]. ORR was 55% and CR was 30%. There was no grade 3/4 hematological toxicity.

Bortezomib: Bortezomib is a proteasome inhibitor. Fifteen relapsed CTCL or PTCL patients got in a phase II trial. ORR was 67% and CR was 13%. The most common grade 3 toxicities were neutropenia (13%), thrombocytopenia (13%) and sensory neuropathy (13%) and there was no grade 4 toxicity [40]. The NCCN has recommended bortezomib as a second-line therapy for patients without intention to proceed to transplantation [5].

AG-221: Isocitrate dehydrogenase 2 (IDH2) mutations have been identified in solid tumors and hematologic malignancies eg. glioblastoma, acute myeloid leukemia and myelodysplastic syndromes. AML and MDS patients reached 56% ORR with IDH2 inhibitor (AG-221) in a phase I study [41]. IDH2 mutations are frequent in AITL (20-45%) so IDH2 inhibitor can be effective in this lymphoma type [42,43].

Everolimus: The mTOR pathway is responsible for T cell proliferation. Everolimus is a mTORC1 inhibitor. Sixteen relapsed T cell were treated with everolimus in a phase II study. The ORR was 44% and CR was 6%. Grade 3/4 AEs were anaemia (25%), leukopenia (19%) and thrombocytopenia 13% [44].

Duvelisib: Duvelisib (IPI-145) is an oral phosphatidylinositol 3-kinase inhibitor (PI3K). Sixteen PTCL patients received duvelisib. ORR was 47% and CR was 13% [45].

Nivolumab: Programmed death-1 (PD-1) immune checkpoint pathway help tumour cells to avoid immune surveillance. Nivolumab is a PD-1 inhibitor, which is approved by FDA in the treatment of Hodgkin lymphoma. The activity of nivolumab in other lymphoid malignancies also has been presented [46]. Responses also were seen in 23 patients with T cell, with superior response seen in patients with PTCL. The ORR for patients with T cell was 17%, there was no CR. The ORR in patients with PTCL was 40% and was 15% in those with cutaneous T cell lymphoma [46].

New combination therapy: Brentuximab vedotin-CHP: BV and CHP combination therapy was examined in a phase I open-label

study as frontline treatment in patients with CD30-positive PTCL. Twenty-six patients were treated, all of them achieved an objective response and CR was 88%. Grade 3/4 AEs were febrile neutropenia (31%), neutropenia (23%), anemia (15%) and pulmonary embolism (12%) [47]. A randomized phase III trial is ongoing, comparing BV and CHP combination with CHOP alone.

Alemtuzumab-CHO(E)P: Alemtuzumab is an anti-CD52 monoclonal antibody that causes depletion of CD4 and CD8 T cells as well as B cells. Alemtuzumab combined with CHO(E)P was investigated 29 patients as consolidation therapy in a phase II trial, CR rate was 58.5%. Grade 3/4 toxicities were infections (14%) [48]. Another phase II study investigated combination of alemtuzumab, fludarabine, cyclophosphamide and doxorubicin in 27 PTCL patients' first line treatment and 11 R/R PTCL patients. ORR was 61%, with a CR of 39%. The most frequent grade 3/4 toxicities were leukopenia (95%) and thrombocytopenia (58%). Cytomegalovirus (CMV) reactivation was detected in 12 patients, but only two had CMV disease. Treatment-related deaths occurred in six newly diagnosed and one R/R patient [49]. Alemtuzumab-based therapy was active in PTCL but was associated with significant toxicity.

Bortezomib-CHOP: Forty six patients were treated with bortezomib plus CHOP as firstline treatment. ORR was 76% and CR was 65%. Outcome was similar to CHOP alone. Grade 3/4 neutropenia was in 41% of patients, febrile neutropenia in 30% and thrombocytopenia in 11% [50].

Bortezomib-gemcitabine: Bortezomib with gemcitabine was used in 16 R/R PTCL patients in a phase I/II ORR was 36% and CR was 27% [51].


Gemcitabine-romidepsin: A phase II trial was conducted in R/R PTCL. Twenty patients were treated with combination of gemcitabine plus romidepsin (GEMRO regimen). The ORR was 30%, 3 patients had CR. Two-year OS was 50% and PFS 11.2%. Sixty percent of the patients had grade ≥ 3 thrombocytopenia, half of the patients had neutropenia. The majority of non-hematological toxicities were mild and transient. There was no treatment-related death or toxicity which led to treatment interruption [52].

Gemcitabine-dexamethason-cisplatin: CISL trial investigated GDP (gemcitabine-dexamethason-cisplatin) protocol in 25 R/R PTCL patients. ORR was 72% and CR was 48%. Grade 3/4 neutropenia (16%) and thrombocytopenia (13%) was occurred [53].

Romidepsin-CHOP: Romidepsin plus CHOP was investigated in a phase Ib/II study in first line treatment of 14 PTCL patients. ORR was 78%, CR was 66% [54].

Everolimus-CHOP: A phase II study investigated the efficacy of everolimus plus CHOP therapy for first-line treatment in PTCL. Thirty patients were treated, ORR was 90%, CR was 57%. The CR rate was different among subtypes, all AITL patients had CR whereas PTCL-NOS and ALK-negative ALCL patients showed 63% and 29% CR. Eighty percent of patients suffered grade 3/4 neutropenia and 60% of patients had grade 3/4 thrombocytopenia [55].

Pirarubicin-COP: Pirarubicin is a derivative of doxorubicin, which is less cardiotoxic than the doxorubicin. A retrospective study analysed 56 patients with PTCL-NOS who had received pirarubicin



plus COP or CHOP treatment. Twenty-nine patients received pirarubicin and COP and 27 received CHOP. CR was 52% in both groups and there were no significant differences in 3-year OS and PFS rates. Pirarubicin and COP led significantly better prognosis in low risk patients [56].

Alemtuzumab-CHOP: Phase I trial was conducted in 20 CD52-positive PTCL patients. ORR and CR were 68% and 37%. Grade 3/4 neutropenia were in 70% of the patients and thrombocytopenia 20% [57].

Pralatrexate-CEOP: First-line cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternated with pralatrexat treatment was used in a phase 2 study. Thirty-three PTCL patients were treated with this protocol. ORR was 70% and 52% of the patients had CR. The 2-year OS and PFS were 60% and 39%, so this new combination did not improve outcomes compared to historical data using CHOP. The most frequent grade 3/4 AEs were anaemia in 27% of patients and febrile neutropenia in 18% of patients [58].

Pixantrone-etoposid-bendamustin: Pixantrone is an analogue of mitoxantrone, but it has fewer cardiotoxic effect. A phase 1/2 study (pixantrone, etoposide and bendamustin) is ongoing in B- and T-cell lymphoma patients.

NCCN recommends in second-line therapy as single-agent treatment: clinical trials, belinostat, romidepsin, pralatrexat and brentuximab vedotin in CD30+ PTCL, or combination therapy (eg. DHAP, ESHAP, ICE). Other alternative regimens (eg. bendamustin, gemcitabin, lenalidomid) can also be used (Figure 1)[5].

Conclusion

TCLs are aggressive, heterogenous, rare lymphoma types. There are a lot of subtypes in the WHO 2016 classification, but relatively few patients in Europe and USA, so the diagnosis is usually difficult. CHO(E)P chemotherapy is usually recommended for the first-line treatment, but it is not effective in majority of PTCLs (except ALK+ALCL). Frontline AHSCT is suggested for all other subtypes.

Remission can be reached mostly, if patients undergo AHSCT in CR/CRu, but it is difficult due to the inadequate firstline chemotherapy possibilities, so guidelines recommend patient's treatment in clinical trials. Use of PET/CT is also suggested in the staging and in response assessment. AHSCT can be more successful if PET/CT show CR after chemotherapy. Prognosis is very poor in relapsed patients. Several drugs were tested in the treatment of TCLs in last years, but roaring success was not reached. Long-term remission is the basis of the cure, so better efficiency therapy must be found.

References

- Jaffe ES, Nicolae A, Pittaluga S. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. *Mod Pathol.* 2013; 26: S71-S87.
- Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood.* 2016; 127: 2375-2390.
- Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol.* 2008; 26: 4124-4130.
- Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. *Ann Oncol.* 2013; 24: 857-877.
- NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's lymphoma, Version 3.2016.
- Abouyabis AN, Shenoy PJ, Flowers C, Lechowicz MJ. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis. *Blood.* 2007; 110: 3452.
- Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood.* 2008; 111: 5496-5504.
- Lunning MA. Treatment of Peripheral T-Cell Lymphoma: Many Shades of Gray. *Oncology (Williston Park).* 2015; 29: 545-550.
- Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. *Br J Haematol.* 2010; 151: 159-166.
- Escalón MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. *Cancer.* 2005; 103: 2091-2098.
- Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. *Ann Oncol.* 2008; 19: 958-963.
- Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. *Ann Oncol.* 2014; 25: 2211-2217.
- Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. *Blood.* 2010; 116: 3418-3425.
- Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. *Blood.* 2014; 124: 1570-1577.
- d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. *J Clin Oncol.* 2012; 30: 3093-3099.
- Nademanee A, Palmer JM, Poplewell L, Tsai NC, Delioukina M, Gaal K, et

- al. High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors. *Biol Blood Marrow Transplant.* 2011; 17: 1481-1489.
17. Horwitz SM. Current and novel treatment options for peripheral T-cell lymphoma. *Clin Adv Hematol Oncol.* 2015; 13: 463-466.
 18. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. *J Clin Oncol.* 2013; 31: 1970-1976.
 19. O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, et al. Phase II-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. *J Clin Oncol.* 2009; 27: 4357-4364.
 20. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. *J Clin Oncol.* 2011; 29: 1182-1189.
 21. Piekarczyk RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. *Blood.* 2011; 117: 5827-5834.
 22. Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O, Thieblemont C, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomized, phase 1b/2 study. *Lancet Haematol.* 2015; 2: e160-e165.
 23. O'Connor OA, Masszi T, Savage KJ. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. *J Clin Oncol.* 2013; 31: 8507.
 24. O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. *J Clin Oncol.* 2015; 33: 2492-2499.
 25. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. *J Clin Oncol.* 2012; 30: 2190-2196.
 26. Chihara D, Oki Y. Brentuximab vedotin for treatment of systemic T-cell lymphoma. *Expert Opin Biol Ther.* 2014; 14: 1519-1526.
 27. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. *Blood.* 2014; 123: 3095-3100.
 28. Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. *J Clin Oncol.* 2013; 31: 104-110.
 29. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. *J Clin Oncol.* 2012; 30: 837-842.
 30. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. *J Clin Oncol.* 2014; 32: 1157-1163.
 31. d'Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, et al. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. *Br J Haematol.* 2010; 150: 565-573.
 32. Dueck G, Chua N, Prasad A, Finch D, Stewart D, White D, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. *Cancer.* 2010; 116: 4541-4548.
 33. Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. *Eur J Cancer.* 2013; 49: 2869-2876.
 34. Kanagal-Shamanna R, Lehman NL, O'Donnell JP, Lim MS, Schultz DS, Chitale DA, et al. Differential expression of aurora-A kinase in T-cell lymphomas. *Mod Pathol.* 2013; 26: 640-647.
 35. Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. *J Clin Oncol.* 2014; 32: 44-50.
 36. Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul-Haq M, et al. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. *J Clin Oncol.* 2015; 33: 2399-2404.
 37. Mehta-Shah N, Horwitz S. Therapy for Peripheral T-Cell Lymphomas: Where We Are and Where We Hope to Be. *Oncology.* 2015; 29: 558-559.
 38. Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Cecon M, Mologni L, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. *J Natl Cancer Inst.* 2014; 106: djt378.
 39. Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. *Ann Oncol.* 2010; 21: 860-863.
 40. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. *J Clin Oncol.* 2007; 25: 4293-4297.
 41. Stein E, Tallman M, Pollyea DA, et al. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. *Cancer Res.* 2014; 74: CT103.
 42. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. *Blood.* 2014; 123: 1293-1296.
 43. Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K, et al. Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. *Leukemia.* 2015; 29: 237-241.
 44. Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. *Blood.* 2015; 126: 328-335.
 45. Horwitz SM, Porcu P, Flinn I, Kahl BS, Sweeney J, Stern HM, et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase- γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma. *Blood.* 2014; 124: 803.
 46. Timmerman J, Armand P, Lesokhin AM, Halwani A, Millenson MM, Schuster SJ, et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin Lymphoma: updated results of a phase 1 study (CA209-039). *Hematol Oncol.* 2015; 33: 100-80.
 47. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. *J Clin Oncol.* 2014; 32: 3137-3143.
 48. Binder C, Ziepert M, Pfreundschuh M, Duhren U, Eimermacher H, Aldaoud A, et al. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. *Ann Hematol.* 2013; 92: 1521-1528.
 49. Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, et al. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. *Leuk Lymphoma.* 2010; 51: 447-455.
 50. Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, et al. Bortezomib in

- combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. *Eur J Cancer*. 2012; 48: 3223-3231.
51. Evens AM, Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, et al. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. *Br J Haematol*. 2013; 163: 55-61.
52. Pellegrini C, Doderio A, Chiappella A, Monaco F, Degl'Innocenti D, Salvi F, et al. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. *J Hematol Oncol*. 2016; 9: 38.
53. Park BB, Kim WS, Suh C, Shin DY, Kim JA, Kim HG, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. *Ann Hematol*. 2015; 94: 1845-1851.
54. Dupuis J, Casasnovas R, Ghesquieres H, Morschhauser F, Tilly H, Thieblemont C, et al. A phase Ib trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): The ro-CHOP study. *Blood (ASH Annual Meeting Abstracts)* 2012; 120.
55. Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, et al. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. *Ann Oncol*. 2016; 27: 712-718.
56. Shibata Y, Hara T, Kasahara S, Yamada T, Sawada M, Mabuchi R, et al. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. *Hematol Oncol*. 2015.
57. Buckstein R, Fraser G, Cheung M, Kukreti V, Kuruvilla J, Imrie K, et al. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. *Clin Lymphoma Myeloma Leuk*. 2016; 16: 18-28.
58. Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. *Br J Haematol*. 2016; 172: 535-544.